Drugs / M2ES
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01219192 | Aug 2010 → Dec 2011 | malignant pancreatic neoplasm | Protgen Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT01218880 | Jun 2010 → Jul 2011 | malignant pancreatic neoplasm | Protgen Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT01226030 | Sep 2009 → Apr 2011 | cancer | Protgen Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT01223924 | May → Sep 2009 | cancer | Protgen Ltd | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01099124 | Dec 2009 → Jul 2011 | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M2ES | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01218880 ↗ |
| Known as | polyethylene glycol rh recombinant endostatin | “polyethylene glycol rh recombinant endostatin” NCT01099124 ↗ |
| Modality | Protein / enzyme biologic | “polyethylene glycol rh recombinant endostatin” NCT01099124 ↗ |
| Route | Intravenous | “administered intravenous infusion” NCT01218880 ↗ |